Heat shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study [post]

Ke Su, Yanlin Liu, Pan Wang, Kun He, Fei Wang, Mingyue Rao, Xueting Li, Lianbin Wen, Yanqiong Song, Jianwen Zhang, Tao Gu, Ke Xu (+27 others)
2022 unpublished
BackgroundAlthough the diagnostic value of plasma heat shock protein 90α (HSP90α) in hepatocellular carcinoma (HCC) has been previously reported, the causal effect of plasma HSP90α levels on HCC prognosis remains largely unclear. To this extent, we sought to assess whether plasma HSP90α act as a prognostic factor for HCC patients.MethodsA total of 2150 HCC patients were included in this retrospective study between August 2016 and July 2021. Plasma HSP90α levels were tested within a week prior
more » ... treatment and their association with prognosis was assessed.ResultsAn optimal cut-off value of 143.5 for the HSP90α based on overall survival (OS) was determined using the X-tile software. HCC patients with HSP90α < 143.5 ng/ml (low HSP90α) had longer median OS (mOS) compared to those with HSP90α ≥ 143.5 ng/ml (high HSP90α) (37.0 vs. 9.0 months, P < 0.001), indicating that high HSP90α plasma level is an independent poor prognostic factor for OS in HCC patients. In our subgroup analysis, including supportive care group, surgery group, transarterial chemoembolization (TACE) group, adjuvant TACE group, immune checkpoint inhibitor (ICI) plus targeted therapy group, and TACE plus ICI group, the high HSP90α group demonstrated better OS compared to the low HSP90α group. Moreover, in the supportive care, TACE, ICI plus targeted therapy and TACE plus ICI groups, high HSP90α levels was also an independent poor prognostic factor for OS.Conclusions Our study confirmed that plasma HSP90α could be used as a prognostic biomarker for HCC.
doi:10.21203/rs.3.rs-1635933/v1 fatcat:xnk7rd7povf5bf5npfzfnswqnq